114 related articles for article (PubMed ID: 28237182)
1. Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib.
Peltola KJ; Penttilä P; Rautiola J; Joensuu H; Hänninen E; Ristimäki A; Bono P
Clin Genitourin Cancer; 2017 Aug; 15(4):487-494. PubMed ID: 28237182
[TBL] [Abstract][Full Text] [Related]
2. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
[TBL] [Abstract][Full Text] [Related]
3. Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?
Ivanyi P; Koenig J; Trummer A; Busch JF; Seidel C; Reuter CW; Ganser A; Grünwald V
World J Urol; 2016 Jul; 34(7):909-15. PubMed ID: 26586475
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment Serum Prealbumin as an Independent Prognostic Indicator in Patients With Metastatic Renal Cell Carcinoma Using Tyrosine Kinase Inhibitors as First-Line Target Therapy.
Cai W; Kong W; Dong B; Zhang J; Chen Y; Xue W; Huang Y; Zhou L; Huang J
Clin Genitourin Cancer; 2017 Jun; 15(3):e437-e446. PubMed ID: 28188047
[TBL] [Abstract][Full Text] [Related]
6. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.
Sorich MJ; Kichenadasse G; Rowland A; Woodman RJ; Mangoni AA
Int J Cancer; 2016 May; 138(9):2293-9. PubMed ID: 26685869
[TBL] [Abstract][Full Text] [Related]
8. Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
Keizman D; Rouvinov K; Sella A; Gottfried M; Maimon N; Kim JJ; Eisenberger MA; Sinibaldi V; Peer A; Carducci MA; Mermershtain W; Leibowitz-Amit R; Weitzen R; Berger R
Cancer Res Treat; 2016 Jan; 48(1):281-7. PubMed ID: 25761478
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
[TBL] [Abstract][Full Text] [Related]
10. Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib.
Keizman D; Gottfried M; Ish-Shalom M; Maimon N; Peer A; Neumann A; Hammers H; Eisenberger MA; Sinibaldi V; Pili R; Hayat H; Kovel S; Sella A; Boursi B; Weitzen R; Mermershtain W; Rouvinov K; Berger R; Carducci MA
Oncologist; 2014 Jan; 19(1):51-60. PubMed ID: 24309979
[TBL] [Abstract][Full Text] [Related]
11. Treatment-related deterioration of renal function is associated with the antitumor efficacy of sunitinib in patients with metastatic renal cell carcinoma.
Fukuda H; Kondo T; Iida S; Takagi T; Tanabe K
Urol Oncol; 2016 Aug; 34(8):338.e1-9. PubMed ID: 27085488
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.
Keizman D; Ish-Shalom M; Pili R; Hammers H; Eisenberger MA; Sinibaldi V; Boursi B; Maimon N; Gottfried M; Hayat H; Peer A; Kovel S; Sella A; Berger R; Carducci MA
Eur J Cancer; 2012 May; 48(7):1031-7. PubMed ID: 22409947
[TBL] [Abstract][Full Text] [Related]
13. C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study.
Xu WH; Wang J; Huo DZ; Yin GC; Cao DL; Shi GH; Qu YY; Ye DW; Zhang HL
Med Sci Monit; 2019 Nov; 25():8984-8994. PubMed ID: 31769434
[TBL] [Abstract][Full Text] [Related]
14. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
[TBL] [Abstract][Full Text] [Related]
15. Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma.
Keizman D; Ish-Shalom M; Sella A; Gottfried M; Maimon N; Peer A; Hammers H; Eisenberger MA; Sinibaldi V; Neiman V; Rosenbaum E; Sarid D; Mermershtain W; Rouvinov K; Berger R; Carducci MA
Clin Genitourin Cancer; 2016 Oct; 14(5):420-425. PubMed ID: 27211307
[TBL] [Abstract][Full Text] [Related]
16. Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of sunitinib.
Lu X; Gu W; Zhang H; Zhu Y; Shi G; Ye D
Oncotarget; 2016 May; 7(18):26879-87. PubMed ID: 27058898
[TBL] [Abstract][Full Text] [Related]
17. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D
Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of sunitinib in patients with renal cell carcinoma with bone metastases.
Paule B; Brion N
Anticancer Res; 2010 Dec; 30(12):5165-8. PubMed ID: 21187506
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]